Free Newsletter
European guidelines could spur Multaq use
Free newsletter via e-mail
Tools
In a boost for a drug that started off slow on the sales side, new European medical guidelines recommend Sanofi-Aventis' heart rhythm drug Multaq as a first-line treatment option for patients with atrial fibrillation. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: